TWST - Twist Bioscience Corporation Analysis

One-Sentence Summary of Key Findings

Twist Bioscience (TWST) is a rapidly growing synthetic biology firm with proprietary silicon-chip DNA synthesis technology driving record revenues above $400M TTM, strong double-digit growth, raised FY2026 guidance toward potential adjusted EBITDA breakeven by Q4, and predominantly positive analyst ratings, offset by ongoing net losses, a recent $250M stock offering announcement, and competitive pressures in the genomics space.[Company IR] [Yahoo Finance]

Company Overview and History

Overview (Facts)

Manufactures and sells synthetic DNA-based products using a proprietary semiconductor-based platform that "writes" DNA on silicon chips for higher throughput, lower cost, and scalability compared to traditional methods.
Core products: synthetic genes/gene fragments, oligo pools (for NGS, CRISPR, etc.), NGS library prep tools/panels, and antibody libraries (IgG proteins) for drug discovery.
Applications span therapeutics, diagnostics, industrial chemicals, agriculture, data storage (DNA as medium), and academic research; serves biotech/pharma, industrial, ag, and academic customers globally (majority revenue from Americas).
Headquartered in South San Francisco, CA; ~979 full-time employees; strategic collaboration with bitBiome Inc.
Founded 2013; incorporated in Delaware February 4, 2013; IPO priced October 30, 2018 at $14/share (NASDAQ: TWST).

History (Facts)

Co-founded by Emily Leproust (CEO, ex-Agilent), Bill Banyai, and Bill Peck; Leproust previously worked at Agilent for 13 years.
Early focus on industrializing DNA synthesis; raised significant venture funding (~$321M pre-IPO from investors including Fidelity, Illumina).
2018 IPO marked entry as public synthetic biology company; subsequent growth through product expansion into NGS tools and biologics discovery.
Historical note: Faced early lawsuit from Agilent (settled/resolved); diversified customer base beyond initial large client Ginkgo Bioworks.

Data Limitation: Historical details primarily from company filings and profiles as of mid-2026; full SEC S-1 or 10-K recommended for exhaustive early financials.

More information: Company About Page | Investor Relations | Wikipedia

Stock Performance and Company Financials

Stock Performance (Facts)

All-time high closing price: $207.97 (January 20, 2021).
52-week high: $106.58 (recent period).
Strong YTD performance noted in multiple sources (e.g., +200%+ ranges cited in analyst commentary and performance overviews through early August 2026); outperformed broader market and some synbio peers.
Historical price data available showing volatility typical of growth biotech stocks; 13 consecutive quarters of revenue growth as of Q3 FY2026.

Interpretation: The stock has demonstrated significant appreciation driven by operational momentum and sector interest in synthetic biology/AI-drug discovery applications, though past performance does not guarantee future results.

More information and charts: Yahoo Finance Historical Data | Macrotrends 8-Year History

Company Financials (Facts)

Metric	Recent Period	Prior Comparison	Notes
Q3 FY2026 Revenue	$110.7M	$92.8M (Q3 FY2025)	+19% YoY; exceeded guidance; 13th consecutive growth quarter
FY2026 Guidance (raised Aug 2026)	$456M–$457M	Previous $442M–$447M	Fact from earnings release
Gross Margin (Q3 FY2026)	51.6%	49.6% prior year	Target >52% for full FY; improving trend
Customers Shipped (Q)	~2,583	~2,431 prior year	Growth in base
Adjusted EBITDA Target	Breakeven expected Q4 FY2026	N/A	Forward-looking company statement

Uncertainty: While revenue growth and margin expansion are factual, achievement of profitability targets depends on execution, cost control, and market conditions; net losses persist.

Data Limitation/Assumption: TTM and quarterly figures aggregated from multiple sources (Yahoo, company releases) as of early August 2026; exact fiscal year-end (likely Sept 30) and full 10-Q details should be verified on EDGAR or IR site. No current price shown per guidelines.

More information: Company Press Releases (incl. Q3 FY2026 earnings) | Yahoo Financials | Nasdaq Financials

Analyst Ratings

Consensus and Recent Activity (Facts)

Overall consensus: Moderate Buy to Strong Buy (typically 8–9 Buy/Strong Buy, 1 Hold, occasional Sell or downgrade noted).
Average 12-month price target: Ranges $90–$106 across sources (high $120, low $36–$85); recent post-Q3 earnings upgrades common (e.g., TD Cowen to $115, Canaccord to $120, Piper Sandler to $115, Baird to $115).
Recent examples (Aug 2026): Multiple firms raised targets following strong Q3 results and raised guidance; some reaffirmations at Buy with AI-driven growth outlook cited.
Number of analysts: ~9–11 covering.

Source/Aggregator	Consensus Rating	Avg PT	High/Low
TipRanks	Strong Buy	~$99–$106	$120 / $85
MarketBeat	Moderate Buy	~$90–$95	$120 / $41
Yahoo/Zacks	Buy	~$92–$104	$120 / $36

Interpretation: Elevated targets and upgrades reflect optimism around growth trajectory, NGS/DNA synthesis demand, and path to profitability, but targets can shift rapidly with earnings or market sentiment.

Uncertainty: Analyst ratings and targets are opinions based on models/assumptions; not guarantees, and dispersion (wide high/low range) highlights differing views on valuation and risks.

More information: TipRanks Forecast | Yahoo Analyst Insights | MarketBeat

Customers and Competitors

Customers (Facts)

Broad base of ~2,500–3,500+ customers (Q3 FY2026: ~2,583 shipped to).
Segments: Biotech/pharma (drug discovery, therapeutics), diagnostics, industrial chemicals/materials, agriculture/food, academic/research labs.
Notable: Diversified away from historical concentration (e.g., Ginkgo Bioworks was once large); partnerships include Illumina (NGS integration) and bitBiome.
Products used in NGS sample prep, CRISPR, antibody engineering, viral controls/panels, and emerging DNA data storage.

Competitors (Facts)

Competitor	Key Overlap	Notes/Comparison
IDT (Integrated DNA Technologies), GenScript, Agilent	Traditional chemical DNA synthesis, NGS tools	Established players; Twist claims advantages in cost/scale/speed via silicon platform (limitation: shorter max fragment lengths)
Ginkgo Bioworks (DNA)	Synbio platforms, DNA synthesis demand	Former large customer; now peer/competitor in engineered biology
Illumina, Qiagen, Thermo Fisher	NGS/sample prep, genomics tools	Twist partners with some (e.g., Illumina); competes in panels/kits; Qiagen has larger reported market share in some segments
Emerging: Enzymatic synthesis firms (e.g., Catalog, others)	Next-gen DNA writing tech	Potential long-term disruptors to chemical/silicon methods
Others: Veracyte (VCYT), Moderna (MRNA - tangential)	Diagnostics/therapeutics applications	Indirect via end-markets

Interpretation: Twist differentiates via its silicon platform for high-volume, high-quality synthesis, enabling competitive pricing and volume; however, faces entrenched competitors and technological evolution risks.

Uncertainty: Market share and competitive dynamics evolve; exact customer concentration or win rates not fully disclosed publicly.

More information: MarketBeat Competitors | CB Insights

Overall Data Limitations and Assumptions: All information compiled from publicly available web sources (company IR, Yahoo Finance, analyst aggregators, news) as of approximately August 4–5, 2026. Financial figures are TTM or quarterly snapshots and subject to restatement. Analyst data aggregates multiple providers and changes frequently. No investment advice; verify latest filings (10-Q, 8-K) and consult professionals. Stock performance excludes current price per guidelines.

TWST Stock Analysis: Twist Bioscience Corporation